Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-na ïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study.

Conclusion: Treatment with AAP plus ADT has shown a positive risk-benefit balance and may serve as a new treatment option to improve the prognosis of Japanese mHNPC patients with high-risk features.
PMID: 30371895 [PubMed - in process]

Source: Clinical Breast Cancer - October 30, 2018 Category: Cancer & Oncology Authors: Fukasawa S, Suzuki H, Kawaguchi K, Noguchi H, Enjo K, Tran N, Todd M, Fizazi K, Matsubara N Tags: Jpn J Clin Oncol Source Type: research